Graybug Vision secures £66m to advance retina and glaucoma clinical programs
Proceeds from the financing will be used to progress GB-102, the company’s lead asset, into both a phase 2b clinical study (the ALTISSIMO study) in wet AMD as
Proceeds from the financing will be used to progress GB-102, the company’s lead asset, into both a phase 2b clinical study (the ALTISSIMO study) in wet AMD as
Recruitment in the trial is underway and the first patient has been enrolled. The Company anticipates reporting top-line data from this trial in the second half of 2020.
The investment secured by Sanfer is expected to help the company implement its continued expansion plans in Mexico and in other parts of Latin America. Additional terms of
RINVOQ is expected to be available in the U.S. in late August 2019. The FDA approval of RINVOQ is supported by data from the SELECT program, one of
“We are excited about the validation of this application which is an important milestone in our ongoing work to improve the lives of people living with rheumatoid arthritis
The late-stage study called PAOLA-1 evaluated Lynparza plus bevacizumab in the first line maintenance setting in comparison to bevacizumab alone in women with advanced ovarian cancer, irrespective of
The IXORA-R trial is the first completed head-to-head (H2H) trial between an IL-17A inhibitor and an IL-23/p19 inhibitor using the Psoriasis Area Severity Index (PASI) 100 score as
CARES10 is a United States/Canada-based open-label, prospective, multi-center phase 3 clinical study to assess efficacy, safety and pharmacokinetics of a 10 percent intravenous immunoglobulin in the treatment of
In this regard, Boehringer Ingelheim and MD Anderson plan to set up a joint Virtual Research and Development Center to facilitate effective data sharing and analysis among themselves.
Ascletis’ Clinical Development Shanghai Center is at the heart of Shanghai, located at Jing’an Kerry Centre near Nanjing West Road. The opening ceremony was held on Aug 11,